Company news
Rhythm Biosciences Limited (ASX:RHY) news
Rhythm Biosciences Limited news releases on 6ix. Latest, Dec 1, 2021: Board and Management Restructure
Press releases — page 3
Board and Management Restructure
November 30, 2021
CE Mark Granted for ColoSTAT
November 29, 2021
Rhythm Biosciences : Change of Director's Interest Notice x 4
November 25, 2021
Application for quotation of securities - RHY
November 12, 2021
RHY - Institutional Investor Presentation
November 9, 2021
ColoSTAT Test Kits Deliver Consistent, High Accuracy Results
October 20, 2021
Rhythm Receives $2.4m R&D Tax Incentive
October 4, 2021
Rhythm Completes Recruitment for Clinical Trial (Study 7)
September 21, 2021
TGA Accepts Initial Regulatory Documentation
September 14, 2021
Rhythm Completes Strongly Oversubscribed $4.3M Rights Issue
September 7, 2021
Initial TGA Regulatory Documentation Submitted
August 18, 2021
Non Renounceable pro rata offer - Completion of despatch
August 9, 2021
Rights Issue Investor Presentation
July 30, 2021
Non renouneable rights issue prospectus
July 29, 2021
Rhythm Establishes US Entity To Drive US Expansion Strategy
July 14, 2021
Rhythm to Present at MST Access Investor Conference
June 17, 2021
RHY adds Sonic Clinical Services to ColoSTAT Clinical Trial
June 15, 2021
FY22 Strategic Update
May 17, 2021
Rhythm Betters ColoSTAT Results
May 5, 2021
Rhythm Extends ColoSTAT Clinical Trial to Western Australia
April 12, 2021
Rhythm Retains ISO13485 Certification
March 30, 2021
Study 6 Successfully Concluded - Exceptional Results
March 15, 2021
Rhythm Expands ColoSTAT Clinical Trial To Tenth Site
February 10, 2021
Initial Manufacturing of ColoSTAT Test-Kits Complete
January 19, 2021
Rhythm Advances ColoSTAT Study 7
January 18, 2021
Investor Presentation - December 2020
December 20, 2020
Rhythm Secures US Patent - Strengthens Global Footprint
December 16, 2020
Rhythm Appoints Global Manufacturer for ColoSTAT
December 1, 2020
AGM Presentation - November 2020
November 17, 2020
ColoSTAT Prototype Complete, Outperforms FIT
November 11, 2020
Ethics Approval Received, New Clinical Trial Site Added
October 26, 2020
Rhythm Receives $1.1m R&D Tax Incentive
October 15, 2020
Final Two Adjunct Biomarkers Technically Validated
September 28, 2020
New Clinical Trial Site Contracted and Recruiting
September 22, 2020
Rhythm Successfully Validates Two Adjunct Biomarkers
September 15, 2020
Revised CEO Contract and LTIP for all employees - amended
September 14, 2020
Revised CEO Contract and LTIP initiated for all employees
September 13, 2020
Addtl Clinical Trial Site Signed - First Patient Recruited
September 9, 2020
Non-renounceable rights issue Offer
July 31, 2020
Placement & Rights Offer to raise approximately $6 million
July 22, 2020
COVID-19 Update
April 8, 2020
Successful ISO13485 Surveillance Audit
April 5, 2020
Rhythm Successfully Validates Key Biomarker
April 1, 2020
Rhythm Biosciences Granted China Patent
November 3, 2019
ColoSTAT - Test Development Update
September 19, 2019
Appendix 4C
July 25, 2019
Rhythm signs Alfred Hospital for ColoSTAT clinical trial
June 26, 2019
Monash Health signed with first patients recruited
June 17, 2019
Rhythm Biosciences receives ISO certification
May 21, 2019
Rhythm recruits first patient in ColoSTAT clinical trial
March 17, 2019